|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
Need a report that reflects how COVID-19 has impacted this market and its growth?
The proton pump inhibitors market was valued at USD 2,750 million in 2020, and it is anticipated to reach USD 3,585 million in 2026, registering a CAGR of nearly 4.5% during the forecast period, 2021-2026.
Many researchers have found that proton pump inhibitors have increased the risk of COVID-19 in patients taking these medications. The researchers of the American Journal of Gastroenterology, in 2020, conducted research in which more than 53,000 people taking proton pump inhibitors participated, out of which 3,386 said that they had tested positive for COVID-19. This factor is expected to affect the market growth as the patients undergoing PPI therapy are advised to consume less medication and avoid these medications unless it is an emergency. Thus, a negative impact because of COVID-19 on this market can be observed.
Proton pump inhibitors are gold standard medication for gastroesophageal reflux disease (GERD), and the increasing prevalence of GERD and the rising acceptance of novel drug delivery systems are the two most prominent factors driving the growth of the market.
GERD has become a common lifestyle problem among the populations in developed and developing regions. Also, for instance, the United States National Library of Medicine (NCBI) published a report in October 2018, which stated that approximately 8.8–25.9% of the population in Europe, 2.5–7.8% in East Asia, 18.1–27.8% in North America, 11.6% in Australia, and 23.0% in South America had gastroesophageal reflux disease (GERD) in that year. Also, according to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, globally, there were 9283 (8189 to 10400) cases per 100,000 population in 2017, and 709 million (626 to 795) people of the world reported GERD in 2017.
According to the Mayo Foundation for Medical Education and Research, risk factors such as aging, obesity, delayed stomach emptying, changing lifestyles associated with smoking, consumption of alcohol, coffee, fatty, and fried foods are the major reasons for the occurrence of GERD. The World Population Ageing Report, 2019, by the Department of Economic and Social Affairs, United Nations, states that in 2019, there were 703 million people aged 65 years or over in the global population, and this number is positioned to double to 1.5 billion in 2050. In addition, players in this market are developing novel products and coming up with new product launches to leverage market opportunities. For instance, in May 2019, Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners signed a collaborative agreement to launch Phathom Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. Hence, the increasing prevalence of GERD, along with the growing risk factor population, is likely to increase the demand for proton pump inhibitors, which in turn, is expected to drive the market. Also, the increasing shift from prescription to OTC drugs is driving the proton pump inhibitors market.
However, the increasing use of generic products in the market and the side effects associated with the drugs are the factors that can hamper the market growth.
Scope of the Report
As per the scope of the report, proton pump inhibitors (PPIs) are a group of drugs whose main action is the long-lasting reduction of gastric acid production. They are the most potent inhibitors of acid secretion available. The proton pump inhibitors market is segmented by drug type (OTC drugs: omeprazole, lansoprazole, esomeprazole, and other OTC drugs; and prescription drugs: rabeprazole, dexlansoprazole, pantoprazole, and other prescription drugs) and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the market size and forecasts in value (USD million) for the above segments.
|By Drug Type|
Key Market Trends
The Esomeprazole Segment is Expected to Account for a Significant Share Over the Forecast Period
As per the financial results released by AstraZeneca, it was reported that the net sales of Nexium (Esomeprazole) declined in Q1 of 2020. The reported sales in Q1 of 2020 were found to be USD 338 million compared to USD 363 million in Q1 of 2019 due to the emergence of COVID-19 and lockdown guidelines and the guidelines by various regulatory bodies to avoid the treatment of proton pump inhibitors. However, later, the sales started resuming, and in Q4, the net sales of Nexium amounted to USD 401 million.
Esomeprazole is considered one of the leading revenue-generating drugs in the market, and it is mostly indicated to treat the symptoms of GERD, heartburn, and other disorders involving excessive stomach acids. The drug was being sold as a prescriptive drug until March 28, 2014, the date when the FDA approved it as an OTC drug. The shift from being a prescription-only drug to being sold as an over-the-counter (OTC) drug is likely to be a major driving force for the sales of the drug in the near future.
In addition, major market players are focused on R&D and market expansion activities to bring new and reliable formulations to the market. For instance, in July 2020, Cadila Pharmaceuticals launched esomeprazole tablets for the treatment of hyperacidity and drug-induced gastritis under the brand name, Esiloc, in India. Thus, owing to all the above-mentioned factors, the Esomeprazole segment is expected to achieve high growth rates.
To understand key trends, Download Sample Report
North America is Expected to Account for the Largest Share of the Market
North America currently dominates the proton pump inhibitors market and is anticipated to show a similar trend over the forecast period, without significant fluctuations. There is a rising burden of GERD in the United States, Canada, and Mexico due to people’s shift toward unhealthy lifestyles. According to a study by Lancet Gastroenterology and Hepatology in 2017, the prevalence of GERD in the United States was the highest, with more than 11,00 cases per 100,000 population. Also, according to a report published by the Journal of Neurogastroenterology and Motility at NCBI, in 2018, approximately 20% of the adults and 18-27.8% of the US population reported the problem of GERD.
Proton pump inhibitors are one of the most widely prescribed drugs, and an increased PPI use has been observed in the US ambulatory settings for the last few years. Furthermore, many firms are spending heavily on promoting their brands. The widespread use of PPIs has also gained attention from the American Board of Internal Medicine; as a result, the board conducted a campaign to promote the appropriate use of PPIs. Moreover, product launches in a generic category are also expected to impact the market. For instance, in January 2019, Dr. Reddy’s launched generic omeprazole delayed-release tablets for the treatment of heartburn in the United States. Hence, the rising expenditure in healthcare, changes in lifestyle, and increasing geographic footprints of the players in this region are expected to boost the market growth.
North America has been one of the worst affected regions by the ongoing COVID-19 pandemic. The growth of the proton pump inhibitors market is expected to slow down to some extent because of the restrictions on the import of several non-essential drugs by the United States Food and Drug Administration and other regulatory bodies in the country.
To understand geography trends, Download Sample Report
The proton pump inhibitors market is a fragmented one, owing to the presence of various players in the market. The market players are focusing on acquiring market shares by focusing on aggressive advertisements and awareness programs among the patients. The major key players in the market include AstraZeneca, Bayer AG, Cadila Pharmaceuticals, GlaxoSmithKline PLC, Johnson & Johnson, and Pfizer.
In March 2020, RedHill Biopharma Ltd (ADR), a biopharmaceutical company focused on gastrointestinal diseases, commercially launched Talicia (omeprazole magnesium, amoxicillin, and rifabutin) in the US market for infections caused by Helicobacter pylori (H. pylori) in adults.
In March 2020, Cipla Limited received the United States Food and Drug Administration approval for the generic Esomeprazole oral suspension for the treatment of gastroesophageal reflux disease in adults.
Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Gastroesophageal Reflux Disease (GERD)
4.2.2 Rising Acceptance of Novel Drug Delivery Systems
4.3 Market Restraints
4.3.1 Increasing Use of Generic Products
4.3.2 Side Effects Related to Proton Pump Inhibitors
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Drug Type
5.1.1 OTC (Over-the-counter) Drugs
184.108.40.206 Other OTC Drugs
5.1.2 Prescription Drugs
220.127.116.11 Other Prescription Drugs
5.2.1 North America
18.104.22.168 United States (By Drug Type)
22.214.171.124 Canada (By Drug Type)
126.96.36.199 Mexico (By Drug Type)
188.8.131.52 Germany (By Drug Type)
184.108.40.206 United Kingdom (By Drug Type)
220.127.116.11 France (By Drug Type)
18.104.22.168 Italy (By Drug Type)
22.214.171.124 Spain (By Drug Type)
126.96.36.199 Rest of Europe (By Drug Type)
188.8.131.52 China (By Drug Type)
184.108.40.206 Japan (By Drug Type)
220.127.116.11 India (By Drug Type)
18.104.22.168 Australia (By Drug Type)
22.214.171.124 South Korea (By Drug Type)
126.96.36.199 Rest of Asia-Pacific (By Drug Type)
5.2.4 Middle-East and Africa
188.8.131.52 GCC (By Drug Type)
184.108.40.206 South Africa (By Drug Type)
220.127.116.11 Rest of Middle-East and Africa (By Drug Type)
5.2.5 South America
18.104.22.168 Brazil (By Drug Type)
22.214.171.124 Argentina (By Drug Type)
126.96.36.199 Rest of South America (By Drug Type)
6. COMPETITIVE LANDSCAPE
*List Not Exhaustive
6.1 Company Profiles
6.1.2 Bayer AG
6.1.3 Cadila Pharmaceuticals
6.1.4 Eli Lilly and Company
6.1.5 Eisai Inc.
6.1.6 GlaxoSmithKline PLC
6.1.7 Johnson & Johnson
6.1.8 Pfizer Inc.
6.1.9 Santarus Inc.
6.1.10 Takeda Pharmaceuticals
6.1.11 Eisai Pharmaceuticals India Pvt. Ltd
6.1.12 Wyeth LLC
6.1.13 Sanofi SA
6.1.14 Perrigo Company PLC
6.1.15 Dr. Reddy's Laboratories
6.1.16 Aralez Pharmaceuticals Inc.
6.1.17 Redhill Pharma Limited
6.1.18 Cipla Limited
6.1.19 Changzhou Siyao Pharmaceuticals
6.1.20 Yangzhou Pharmaceutical
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Global Proton Pump Inhibitors Market market is studied from 2018 - 2026.
What is the growth rate of Global Proton Pump Inhibitors Market?
The Global Proton Pump Inhibitors Market is growing at a CAGR of 4.5% over the next 5 years.
Which region has highest growth rate in Global Proton Pump Inhibitors Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Global Proton Pump Inhibitors Market?
North America holds highest share in 2020.
Who are the key players in Global Proton Pump Inhibitors Market?
Bayer AG, Pfizer Inc., Takeda Pharmaceuticals, AstraZeneca, Cadila Pharmaceuticals are the major companies operating in Global Proton Pump Inhibitors Market.